



MYRIAD

This supplement was developed and provided to the publisher by Myriad Genetic Laboratories, Inc., as a service to the readers of *OBG Management*.

# Elevating Patient Care through Hereditary Cancer Risk Assessment and Management

## How The OB/GYN Specialists incorporated hereditary cancer risk assessment and management into their practice

Testing for hereditary cancer syndromes has received widespread recognition by medical organizations as an important tool to help physicians identify patients with a predisposition to cancer. Recent professional practice guidelines released by the American College of Obstetricians and Gynecologists (ACOG) and the American Society of Clinical Oncology (ASCO) encourage physicians to include assessment and testing for hereditary cancer syndromes as a standard of care.

As physicians strive to provide the best patient care possible, they must do so within a health care system that can be complex and frustrating to contend with. The idea of offering hereditary cancer risk assessment and management at the practice level elicits a number of concerns: How will it impact the number of patients physicians can see on a daily basis? Will the insurance process consume endless hours of staff time? How will the physician interpret and deliver test results?

Incorporating testing into an ob/gyn practice in a way that addresses these concerns and effectively serves patients requires a level of support throughout the process as well as physicians dedicated to preventive care. The OB/GYN Specialists of Voorhees, New Jersey, found the right combination when they began working with Myriad Genetic Laboratories, Inc. in 2007 to offer hereditary risk assessment and management to their patients. The practice—and its patients—have wholly embraced this service and have benefited greatly from it.

### “It was a relief”

Dr Michele Godorecci and Dr Susanne Adamson founded The OB/GYN Specialists in 2006, a practice that reflects their strong commitment to women’s health. At that time, they were aware

### CASE STUDY:

The OB/GYN Specialists of Voorhees, NJ

#### The practice

- Founded by Drs Michele Godorecci and Susanne Adamson in 2006
- Supported by an office manager, 4 medical assistants and 3 receptionists
- Approximately 300 patient visits per week

#### The need

- Management for hereditary cancer syndromes
- Process must be simple, easily executed and accurately delivered

#### The solution

- Hereditary cancer risk assessment including BRACAnalysis® for Hereditary Breast and Ovarian Cancer syndrome and COLARIS® for Lynch syndrome offered by Myriad Genetic Laboratories, Inc.

#### The result

“I can’t even quantify how much this has helped our practice,” says Dr Godorecci.

of testing for hereditary cancer syndromes and had referred some patients to specialized doctors who performed these types of tests. However, the problem they experienced was a lack of follow through. Dr Godorecci explains: “People are very busy. And I think that women who have children tend to put their own health last. It’s very difficult for them to take care of themselves adequately. Unfortunately, it often catches up with them.” And when patients *did* get tested, they didn’t always receive the information they needed to take preventive measures in the event of a positive test.

For example, Dr Godorecci recalls one patient she saw: “She came in with a CAT scan and it was clear she had end-stage ovarian cancer,” she says. “And I felt, what a tragedy that she had taken it upon herself to get assessed and tested for HBOC. But the physician she saw never adequately reviewed her risk of ovarian cancer, and that prophylactic removal of her ovaries may have prevented ovarian cancer and breast cancer. This patient was probably going to die. She had a 17-year-old daughter whom she would probably never see grow up. I thought something really has to change here, because she got half of it right and, unfortunately, the follow through was abysmal.”

When a Myriad representative visited The OB/GYN Specialists in the summer of 2007 and explained how they could incorporate hereditary cancer risk assessment and management into their practice, it was more than an easy decision—it was a relief. “My first words to her [the Myriad representative] were, ‘What has taken you so long?’ because there have been a number of patients I really felt warranted testing,” says Dr Godorecci.

The ability to assess and manage patients at risk for hereditary cancers in their practice fit well with their preventive care philosophy. “We’re here to treat our patients,” says Dr Adamson. “That’s really why we went into this field in the first place. The best way for a cure is early detection, so if we can find things early and be proactive, we’re going to help patients more than we can in any other way.”

By incorporating this service into their practice, doctors Godorecci and Adamson could now make sure patients that received the full benefit of hereditary cancer risk assessment and management—assessment, counseling, and testing—without delay and with proper follow-up.

## Assessing at-risk patients

Identifying patients who may benefit from hereditary cancer testing requires doctors take a more extensive family history. But, that doesn’t mean it needs to take more time or limit the number of patients that can be seen each day. As Dr Adamson points out, “You always have patients who have other problems than what they are coming in for, and I don’t think this extensive history taking adds more time than anything else.”

To facilitate the process, the doctors at The OB/GYN Specialists use a more detailed family history form (FIGURE). “We have a special form that all our patients fill out. It provides details of the family history better than our standard forms do,” says Dr Adamson.

Since the majority of their patients come in for annual exams, the doctors have them fill out the form

**FIGURE** Family history form

### Family History Questionnaire for Common Hereditary Cancer Syndromes

Patient Name: \_\_\_\_\_ Physician: \_\_\_\_\_

Date Completed: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Please mark below if there is a personal or family history of any of the following cancers. If yes, then indicate family relationship and age at diagnosis in the appropriate column. Consider parents, children, brothers, sisters, grandparents, aunts, uncles, and cousins.

	YOU	Age at Diagnosis	SIBLINGS/CHILDREN	Age at Diagnosis	MOTHER'S SIDE	Age at Diagnosis	FATHER'S SIDE	Age at Diagnosis
For example: Colorectal cancer	none	—	Brother	35 yo	Aunt Cousin	44 yo 33 yo	Grandfather	65 yo
<b>BREAST AND OVARIAN CANCER</b>								
Breast cancer								
Ovarian cancer								
Breast cancer in both breasts OR multiple primary breast cancers								
Male breast cancer								
Are you of Ashkenazi Jewish descent?	<input type="checkbox"/> Yes <input type="checkbox"/> No							
<b>COLON AND UTERINE CANCER</b>								
Uterine (endometrial) cancer								
Colorectal cancer								
Ovarian, stomach, kidney/urinary tract, brain, OR small bowel cancer								
10 or more cumulative colon polyps								
<b>MELANOMA</b>								
Melanoma								
Pancreatic cancer								
<b>OTHER CANCER</b>								
<b>HAVE YOU OR ANY MEMBER OF YOUR FAMILY EVER BEEN TESTED FOR HEREDITARY RISK OF CANCER?</b>								
<input type="checkbox"/> Yes <input type="checkbox"/> No If yes, please explain: _____								
<b>FOR OFFICE USE ONLY</b>								
<input type="checkbox"/> Patient appropriate for further risk assessment and/or genetic testing <input type="checkbox"/> BRACAnalysis® — A test for Hereditary Breast and Ovarian Cancer Syndrome <input type="checkbox"/> COLARIS® — A test for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) <input type="checkbox"/> COLARIS AP® — A test for Adenomatous Polyposis Syndromes <input type="checkbox"/> MELARIS® — A test for Hereditary Melanoma				<input type="checkbox"/> Discussed hereditary cancer risk with patient <input type="checkbox"/> Patient offered genetic testing <input type="checkbox"/> ACCEPTED <input type="checkbox"/> DECLINED <input type="checkbox"/> Follow up appointment scheduled Date: _____				
<small>Myriad Genetic Laboratories, Inc. • 330 Wakarusa Way • Salt Lake City, UT 84108-1214 • 1-800-469-7423 • www.myriadtest.com                  Myriad, the Myriad logo, BRACAnalysis, COLARIS, COLARIS AP, and MELARIS are either trademarks or registered trademarks of Myriad Genetics, Inc., in the United States and other jurisdictions. ©2010, Myriad Genetic Laboratories, Inc. FHQ01-10 MYRIAD®</small>								

each year as a standard part of their visit. This allows the physicians to monitor patients and recommend testing if the responses on the form change. When a patient has an obvious family history of cancer, such as a sister or mother with breast cancer, it is easier to know they should be tested. However, when the patient has more distant or sporadic history of cancer, it can be more difficult to determine if a patient warrants testing. For these complex cases, Dr Adamson says that they call Myriad's medical service team for guidance.

## Educating patients and answering questions

Advising a patient to consider testing can create worry—not only for the patient, but also for close family members who may also need to be tested. Drs Godorecci and Adamson have found that the best way to address patient concerns is to provide complete information.

“We take the time now to go through and explain to patients what their risk really is and how we can make a difference if they test positive or negative. They appreciate the time we have spent with them and the fact that we care enough to talk about this,” says Dr Godorecci.

They also give their patients a Myriad DVD and brochure about hereditary cancer to allow patients to self educate.

## Managing insurance claims

Insurance companies have made great progress in processing claims for hereditary cancer testing. Although each case is unique, their experience has shown 90% of insurance companies now cover the cost of the test as well as any necessary follow-up visits or preventive procedures. Additionally, the average patient pays co-insurance of less than 10% of test cost, and a majority of patients have no out-of-pocket costs. Dr Adamson has found that insurance issues are minimal. “We don't have many problems with insurance,” she says. “Myriad provides helpful insurance support.”

However, for both doctors, no insurance requirement is great enough to risk a patient's life. Dr Godorecci had a patient experience that left a lasting impression on her. When she first started assessing and

testing patients, for hereditary cancer, some insurance companies would deny claims, regardless of the patient history. Dr Godorecci would then have to provide additional documents, including a letter of medical necessity, to appeal the decision. This was an extremely time-consuming process, and she questioned whether it was worth the time.

One day another doctor's patient came in for a visit because that doctor was on disability. The patient was 41, and in the course of interviewing her, Dr Godorecci discovered that the patient's 51-year-old sister had survived a cancer she had been diagnosed with at age 32. Despite the red flag, Dr Godorecci wavered on testing her. “I felt boy, if she had this certain insurance I'm not even going to bother to test her because I know what they were going to say. And I looked and she didn't have it, so I tested her and she was one of my first positives. I thought, never again am I going to decide whether or not to test somebody based upon their insurance. . . I shudder to think what could have happened. It was a good lesson for me.”

## Delivering test results

Whether the results are positive or negative, being tested and receiving the results can be a life-changing event for patients. Patients who test positive can be understandably upset, but by working with us, they gain the opportunity to immediately put into place a plan of action to proactively combat the possibility of cancer—in other words, these patients gain a sense of control. Patients who test negative often feel a sense of empowerment for proactively choosing to be tested in the first place. These patients will then be managed based on their personal and family histories.

Counseling patients about their test results can initially be a difficult task for doctors. To prepare themselves to meet with patients and answer questions, doctors can call Myriad's medical services team, whose members are available Monday through Friday, online, by phone, or in person. When they first started testing, Drs Godorecci and Adamson often contacted this team before discussing results with patients.

Over time, it becomes easier to discuss results. “You learn a lot with the first patient,” Dr Adamson says. “That's when you really get into it deeply with the Regional Medical Specialists before you present to the patient.” She has also learned that “patients need to understand that they don't get a result and have to be scared the rest of their lives—they get a result and then

together, we act proactively to combat the possibility of cancer." The doctors make a point of staying current on research and clinical guidelines.

"I never want to be responsible for missing something," Dr Godorecci explains. "I don't want to find out 5 years from now that I should have done something and now there's somebody who is being visited by hospice because I didn't do my job."

When a patient schedules an appointment to discuss test results, Dr Godorecci suggests that she bring someone with her—a spouse, a family member, a good friend—who can act not only as a second set of ears but a questioner in their own right. The goal is to make sure the patient is supported and fully informed and knows how to proceed.

"If you are not counseled adequately from the get-go on the importance of screening, you don't realize how important it is," Dr Godorecci says. "Because if nobody educates you about what your risk really could be, you might not take it seriously."

### Measuring the impact of hereditary cancer management

Since incorporating hereditary cancer risk assessment and management services into their practice, Drs Godorecci and Adamson have seen many benefits for their patients and their practice.

"I can't even quantify how much this has helped our practice," says Dr Godorecci. "Testing really doesn't limit how many patients we can see," she explains, "I would say the ones that take longest are the positive patients, and thankfully there are not that many,

compared to the total number of patients we see (daily). I usually save the last consult of the day to spend a lot of time to see those patients."

Through word-of-mouth, passed from one patient to another, the two doctors have gained a reputation for being very thorough. "That's the kind of physician patients would prefer to see," says Dr Godorecci. "It is mind boggling how many referrals you get. So you're going to build your practice, which you can't put a price on."

Dr Godorecci understands that some physicians can be uncomfortable taking care of patients when they really don't know how to approach hereditary cancer risk assessment and management. In such situations, she believes that these physicians should at least know which patients should be tested and have a list of specialists for patient referral.

In the end, it all comes down to patient care, which, according to Dr Godorecci, means something different to each doctor. "You have to take care of the patient. You can't *not* counsel them because you're worried about your office hours. You have to take the time out for this counseling session."

#### >> Learn more

To learn how to incorporate hereditary cancer risk assessment and management into your practice, please call Myriad at 800-469-7420 or visit the provider site at [www.myriadtest.com/provider](http://www.myriadtest.com/provider).

#### >> About Myriad Genetic Laboratories

Myriad Genetic Laboratories is a leader in testing for hereditary cancer syndromes. Myriad offers the most accurate clinical tests available to determine predisposition to cancer: BRAC*Analysis*® for hereditary breast and ovarian cancer, COLARIS® for Lynch syndrome, COLARIS AP® for hereditary colorectal polyps and cancer, and MELARIS® for hereditary melanoma and pancreatic cancer.